📣 New GI CONNECT podcast episode 📣 Chemotherapy strategies that matter in mPDAC ➡️ How to choose and optimise the different chemotherapeutic options at 1st & 2nd line w/ Prof. Dr. Shubham Pant + Prof. Efrat Dotan MD 📹 Watch the full video/listen on Spotify/Apple:

📣 New GI CONNECT podcast episode 📣 Chemotherapy strategies that matter in mPDAC ➡️ How to choose and optimise the different chemotherapeutic options at 1st & 2nd line w/ Prof. Dr. Shubham Pant + Prof. Efrat Dotan MD 📹 Watch the full video/listen on Spotify/Apple:

📣 New GI CONNECT podcast episode 📣 Chemotherapy strategies that matter in mPDAC ➡️ How to choose and optimise the different chemotherapeutic options at 1st & 2nd line w/ Prof. Dr. Shubham Pant + Prof. Efrat Dotan MD 📹 Watch the full video/listen on Spotify/Apple:

🔥🔥🔥 New podcast tackling one of the most aggressive and challenging GI cancers 👉Had the pleasure of joining Dr. Efrat Dotan for a meaningful discussion on diagnosis and treatment options in #PancreaticCancer PanCAN Let's Win Pancreatic Cancer 💜 MD Anderson Cancer Center cor2ed.com/gi-connect/pro…

In a feature on #CancerVaccines, we gained insights from: ⭐️ Dr. Shubham Pant of MD Anderson Cancer Center ⭐️ Neal D. Shore, MD, FACS of CURC ⭐️ Glen Gejerman of Hackensack Meridian #Oncology #Vaccines Read the feature here: hubs.li/Q03nDjwj0

🔎 mPDAC is notoriously aggressive w/ poor prognosis Patients are generally Dx’d w/ advanced-stage disease & require chemotherapy as soon as possible Learn more 👇 New podcast episode from Prof. Dr. Shubham Pant and Prof. Efrat Dotan MD 📹 Highlights video in this post Watch the

Discussing 🎯⁦#KRAS with the #Brilliant and #BestDressed ⁦ASCO⁩ #ASCO25 Rachna Shroff, MD, MS, FASCO⁩ ⁦MD Anderson Cancer Center⁩ ⁦PanCAN⁩ ⁦Let's Win Pancreatic Cancer 💜⁩

This #ASCO was special as it was a celebration of success of our Junior Faculty and fellows who SHOWED UP!!! Officially in the ranks of “Senior Author” 😄😄😄 #endcancer ASCO MD Anderson Cancer Center

Metastatic pancreatic ductal adenocarcinoma (mPDAC) ➡️ notoriously aggressive ➡️poor prognosis ➡️often diagnosed late ➡️surgery is usually not an option This is why chemotherapy strategies really matter Podcast discussion from Prof. Dr. Shubham Pant & Prof. Efrat Dotan MD Watch

Paulo Amaral, MD Brian Rini, MD Integrity CE, LLC Rana McKay, MD, FASCO Sumanta K. Pal, MD, FASCO Katy Beckermann Joseph Vento, MD, MS Miguel Zugman Toni Choueiri, MD Tom Powles Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) KidneyCAN 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 jc Alan Tan Uromigos Laurence Albiges Andrey Soares Sahil Doshi Gabriel Aleixo James Brugarolas Yu-Wei Chen, MD, MS Hans Hammers #TumorBoardTuesday I hope everyone in the US🇺🇸is able to enjoy a peaceful and festive 4th of July🎆 📢Then we'll see you back here 07/08/2025 as the omnipresent & infamous Dr. Shubham Pant and the⬆️⭐️Daniel Haldar from MD Anderson Cancer Center 🗣️treatment options in #PancreaticCancer

📣 GI CONNECT podcast episode 📣 ➡️ Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC) Dr. Shubham Pant & Prof. Efrat Dotan MD discuss chemotherapy strategies that matter Conversation topics include: - Efficacy & safety profiles - Relevance of mode of delivery - Cause of

And that’s a wrap on #ESMOGI in vibrant Barcelona! Honored to chair the #KRAS in pancreatic cancer symposium, present the COMBAT-Pancreatic Cancer trial, and reconnect with amazing colleagues. Until next time—Adios Barcelona! 🇪🇸 Rachna Shroff, MD, MS, FASCO

#TumorBoardTuesday 😮We had a rare #ASCO25 with several key🗝️updates in #PancreaticCancer So to put this in context: 📢Join us Tuesday, 07-08-25 at 8PM ET as Dr. Shubham Pant & Daniel Haldar 🗣️Optimizing 1L Treatment Selection in mPDAC RT and bring others into the discussion‼️

#TumorBoardTuesday 1/18 #TumorBoardTuesday #OncTwitter Today’s case: 61 yo 👩🏻, professional violinist 🎻 Abdominal pain + weight loss x 3 months ECOG 1 CT A/P: 3.2-cm pancreatic head mass, +liver lesions

Excited for the discussion

#TumorBoardTuesday Dr. Shubham Pant Mike Pishvaian Brandon Smaglo Dr. Neeha Zaidi Rohit Thummalapalli Nicholas Hornstein Shruti Patel, MD Ryan Huey, MD, MS Saumya Maru M.D., Ph.D. Madhu Eluri, MD Ethan Ludmir MD A pancreatic cancer doctor Tanios Bekaii-Saab, MD Wungki Park, MD MS Mark Lewis, MD, FASCO Anirban Maitra Arndt Vogel Oncology Brothers 7/18 #TumorBoardTuesday 🌍 NAPOLI-3: randomized, open-label, global Ph3 trial (n=770) @LancetOncol ⚖️ NALIRIFOX > Gem+nab-P in 1L metastatic PDAC 🟢 Median OS: 11.1 mos 🆚 9.2 mos (HR 0.83; p=0.036) 🟢 Median PFS: 7.4 mos 🆚 5.6 mos (HR 0.70; p<0.0001) 🟡 ORR: 41.8%

#TumorBoardTuesday Dr. Shubham Pant Mike Pishvaian Brandon Smaglo Dr. Neeha Zaidi Rohit Thummalapalli Nicholas Hornstein Shruti Patel, MD Ryan Huey, MD, MS Saumya Maru M.D., Ph.D. Madhu Eluri, MD Ethan Ludmir MD A pancreatic cancer doctor Tanios Bekaii-Saab, MD Wungki Park, MD MS Mark Lewis, MD, FASCO Anirban Maitra Arndt Vogel Oncology Brothers 18/18 #TumorBoardTuesday 🎯Key takeaways, cont’d: 💰Financial toxicity of NALIRIFOX = major concern 💩Caution re: increased risk of GI side effects (diarrhea, n/v) 💡May consider NALIRIFOX in select pts due to ⬇️neuropathy + BM suppression

Had a Gr8 discussion with Rachna Shroff, MD, MS, FASCO on one of my fav topics: Molecular Profiling in Pancreatic Cancer, with a deep dive into RAS testing and codon-specific interpretation!! 💥 Watch this space—more discussions and insights to come!!! onclive.com/view/molecular… via @onclive

Frontline Tx regimens in mPDAC should be individualised based on: 🔸performance status 🔸comorbidities 🔸risk of neuropathy 👉 FOLFIRINOX, NALIRIFOX, and gemcitabine/nab-paclitaxel all offer survival benefit with distinct toxicity profiles What else do HCPs need to know about

Received a Texas sized farewell from my MD Anderson Cancer Center family, complete with an exceptional brisket from top chef Eugene J. Koay, MD, PhD. Thanks to Stacy & Eugene for hosting and the gang for 12 AMAZING years of friendship & collaboration (both keep going!) Grateful to all of you 🙏🏽🙏🏽